{"title": "Find a Doctor", "author": null, "url": "https://www.dana-farber.org/find-a-doctor/nikhil-c-munshi/", "hostname": "dana-farber.org", "description": "Nikhil C. Munshi, MD - Medical Oncology. Dr. Munshi received his MD from Maharaja Sayjirao University, India, in 1984. He completed his postgraduate training in Internal Medicine at SSG Hospital and Maharaja Sayjirao University, followed by fellowships at Johns Hopkins Oncology Center and Indiana University Medical Center. In 2001, he joined Dana...", "sitename": "Nikhil C. Munshi, MD - Dana-Farber Cancer Institute", "date": "2019-09-12", "cleaned_text": "promises. Blood. 2023 07 27; 142(4):313-324. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37196627) Respiratory Infections Predominate after Day following B-Cell Maturation Antigen-Directed CAR T-cell Therapy. Blood Adv. 2023 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37486599) Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel. Blood Cancer Discov. 2023 Jul 24. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37486974) Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma. Clin Cancer Res. 2023 Jul 18. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37463058) DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification. Haematologica. 2023 Jul 13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37439377) Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36877894) Ubiquitin receptor PSMD4/Rpn10 is a target myeloma. Blood. 05 25; 141(21):2599-2614. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36630605) Cell Cycle Genomic Evolution, and Chemoresistance myeloma. Blood. 2023 04 06; 141(14):1724-1736. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36603186) Analysis of patient-reported experiences 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial. Leuk Res. 2023 06; 129:107074. the breakpoint within the NSD2 gene identifies a subset patients with high-risk NDMM. Blood. 2023 03 30; 141(13):1574-1583. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35984902) Report of consensus panel 7 from the 11th international workshop on Waldenstr\u00f6m macroglobulinemia on priorities for novel clinical dynamic prognostic in multiple View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36409606) Whole-genome analysis novel drivers and high-risk double-hit events in relapsed/refractory myeloma. Blood. 2023 in: long noncoding RNA an essential chromatin scaffold for protein interaction and myeloma growth. Blood. 2023 01 26; 141(4):391-405. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36126301) Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma. Cancers (Basel). 2023 Jan 15; 15(2). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36672481) Improving NK cell function with NKTR-255, a novel polymer-conjugated human 7(1):9-19. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35882498) Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System. Pharmacoepidemiol Drug Saf. 2023 05; 32(5):558-566. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36458420) In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors. Blood Cancer J. 2022 12 20; 12(12):171. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36535935) Author Correction: Functional dissection of non-coding variation multiple myeloma 13(1):7725. in DNA Damage, Chemoresistance and Immune Dysregulation in Solid Tumors. Cancers (Basel). 2022 Nov 20; 14(22). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36428789) Recent common human coronavirus infection protects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A Veterans Affairs cohort study. Proc Acad S A. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36343242) In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36343306) Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. Blood Adv. 2022 09 13; Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders. Blood. 2022 08 18; 140(7):782-785. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35605185) ?-secretase antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer 2022 08 12(8):118. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35973981) Comprehensive refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. Haematologica. 2022 08 01; 107(8):1891-1901. View in: after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient Leuk Res. 2022 09; 120:106921. View for SRC family kinase HCK as a driver of until Progression in Myeloma. N Engl J Plasma Transcriptomic 22; 6(4):1309-1318. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34933328) Quality of life, psychological distress, and prognostic perceptions in patients with multiple 2022 02 10; 13(1):807. View in: value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, 02 10; 139(6):835-844. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34289038) Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022 Feb; 9(2):e143-e161. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35114152) Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34653241) Cell-free DNA the detection of emerging treatment in relapsed/ refractory multiple myeloma. Leukemia. 2022 dissection multiple of cells by interfering with IL-4/IL-4R signaling proliferation, and further CCL20 through a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. APOBEC3G damage and promotes genomic instability in multiple myeloma. Blood Cancer J. 2021 10 08; 11(10):166. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34625538) Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clin Cancer Res. 2021 10 Res. 2021 10 01; 27(19):5376-5388. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34301753) Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study. Blood The DNA of multiple myeloma shows inter- and intrapatient Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. J Natl Cancer immunosuppression in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 398(10297):314-324. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34175021) Detection of minimal residual disease by next generation sequencing in AL amyloidosis. Blood Cancer J. 2021 06 21; 11(6):117. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34155198) Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. Am J Hematol. 2021 08 01; 96(8):896-900. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34057243) Contemporary Analysis of Electronic Frailty Measurement in Older Adults with Multiple Myeloma Treated in the National US Veterans Affairs Healthcare System. Cancers (Basel). 2021 Jun 18; 13(12). View signaling Adv. 2021 06; 7(23). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34088671) Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. J 2(4):370-387. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34258103) miR-15a/16-1 deletion in B cells promotes plasma cell and mature B-cell neoplasms. Blood. 2021 04 08; 137(14):1905-1919. of relapsed and refractory multiple myeloma: recommendations from the International Myeloma [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33626253) Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 02 08; of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e119-e130. View Identification target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13. Cancer J. 2021 01 13; 11(1):13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33441535) Risk factors in multiple myeloma: is it time for a revision? Blood. features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020 12 24; 136(26):3033-3040. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33367546) A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020 12 08; 4(23):5988-5999. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33284948) International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020 MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. Cancer Res. 2021 02 01; 81(3):713-723. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33288657) Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset. Blood. 2020 Nov 06. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33156904) VIS832, a novel CD138-targeting monoclonal antibody, induces of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. Blood Cancer J. 2020 11 02; 10(11):110. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33149123) Don't Compromise Myeloma Care Cancer Discov. 2020 11; 1(3):218-220. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34661145) Revealing the impact of structural in multiple Blood Cancer Discov. the potency of AMG 701 in multiple myeloma preclinical models. 2020 09 08; 4(17):4195-4207. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32898244) YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32187357) Genome-Wide Somatic Alterations in Reveal a Outcome Group. J Clin Oncol. 2020 09 20; of CD8+ anti-BCMA mRNA CAR T for treatment Leukemia. 2021 03; 35(3):752-763. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32632095) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J against 34(7):1971. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31949267) Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32533060) Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32442065) Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma. Blood Adv. 2020 04 28; 4(8):1643-1646. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32315398) Timing the of 04 21; 11(1):1917. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32317634) c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. Eur J View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32145111) Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. Cancer Res. 2020 05 15; 80(10):2031-2044. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32193289) Moving From Cancer Burden Cancer Genomics for Myeloma: A Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020 07; 34(7):1866-1874. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32060406) The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. 2020 12 10; 3(23):3968-3972. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31805191) Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. Blood Adv. 2019 11 12; 3(21):3360-3374. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31698464) Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020 02; plerixafor combination with bortezomib as a chemosensitization relapsed/refractory multiple Hematol. 2019 11; 94(11):1244-1253. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31456261) Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2020 01; 26(1):e7-e15. View in: Gammopathy 01; 5(9):1302-1303. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31318381) Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. against 01; 34(1):210-223. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31427721) Author Correction: A practical mutational signature in hematological Nat Commun. 2019 Jul 10(1):3431. View in: practical for mutational in Nat Commun. 2019 10(1):2969. The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. Leukemia. 01; or refractory multiple myeloma: I 2019 05 02; 380(18):1726-1737. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31042825) Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019 07 11; 134(2):160-170. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31043423) With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood. 2019 06 13; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31003998) Cancer J. 2019 03 26; 9(4):39. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30914633) Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in Leuk. 2019 J. 2019 Jan/Feb; 25(1):45-53. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30694859) Introduction by the Guest Editor: At a Crossroad to Cure: From Molecule to Management Strategies in Multiple Myeloma. Cancer J. 2019 Jan/Feb; 25(1):1. View 26; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30590042) Variable BCL2/BCL2L1 ratio 2018 12 27; 132(26):2778-2780. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30401751) Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Res. 2019 01; 7(1):100-112. of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2019 03; 25(3):e89-e97. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30408566) The roles of homologous recombination and the immune system in the genomic evolution of cancer. J Transl Sci. 2019 Apr; 5(2). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30873294) Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance. Blood Cancer J. 2018 09 25; 8(10):92. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30301882) A multiple myeloma classification system associates normal B-cell subset phenotypes with Blood Adv. 2018 09 25; 2(18):2400-2411. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30254104) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 12 06; 132(23):2456-2464. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30249784) Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenstr\u00f6m Macroglobulinemia. Clin Cancer 25(1):369-377. International, evidence-based consensus treatment guidelines idiopathic multicentric disease. Blood. 2018 11 15; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30181172) APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: implications. Leukemia. 2019 02; 33(2):426-438. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30135465) Genomic patterns of progression Commun. 2018 08 22; 9(1):3363. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30135448) The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 2018 View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29997223) A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. 2019 01; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29967379) Multiple 12; 32(12):2636-2647. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29895955) Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 08 09; 132(6):587-597. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29884741) Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018 12; 32(12):2604-2616. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29789651) A phase 2 study lenalidomide, bortezomib and dexamethasone in transplant-ineligible intergenic non-coding RNAs have an independent impact on survival in myeloma. Leukemia. 2018 12; 32(12):2626-2635. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29749396) 08; 32(8):1838-1841. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29749395) Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Multiple cytotoxic T lymphocytes against multiple myeloma and tumors. of and myeloma activity. CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biol Blood Marrow Transplant. 2018 04; 24(4):641-648. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29242112) Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2017 Dec 06. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29209042) Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia. 2018 04; 32(4):1044-1048. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29209044) Expressed fusion gene landscape and its impact in multiple myeloma. Nat methyltransferase 5 has relevance and is a druggable target in multiple myeloma. Leukemia. 2018 04; 32(4):996-1002. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29158558) Determining therapeutic susceptibility in multiple single-cell Nat Commun. 2017 11 14-3-3? binds proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. Leukemia. 2018 03; 32(3):744-751. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28924240) Logic programming reveals alteration of key transcription factors in multiple myeloma. Sci Rep. 2017 08 23; 7(1):9257. 3(8):1136-1137. View Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28686535) ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell. 2017 07 10; 32(1):88-100.e6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28669490) Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia. 2018 01; 32(1):111-119. View in: a high penetrance of monoclonal gammopathies for the identification of candidate a Therapeutic Target in Multiple Myeloma. Clin Cancer Res. 2017 Sep 01; 23(17):5225-5237. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28442502) The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clin Cancer 06; 376(14):1311-1320. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28379796) The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 04 Repair and Triggers Apoptosis in Myeloma Cells. Clin Cancer CD38 Suppresses and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. Clin Cancer Res. therapeutic targeting of p21-activated kinase 4 in multiple in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28096095) p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 03 09; 129(10):1308-1319. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28082445) Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28197386) A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016 Nov 22; 7(47):77326-77341. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27764795) Gene Expression Profiles in Myeloma: Ready for the Real World? Clin Cancer Res. 2016 Nov 15; 22(22):5434-5442. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28151711) A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer 2016 09 6(9):e467. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27588520) A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 08; 17(8):e328-e346. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27511158) DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining immune suppressive Blood. 2016 09 22; 128(12):1590-603. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27418644) Review of Synergistic Waldenstr\u00f6m Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation View in: CCR6 drives tumor growth through recruitment in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. Blood. 2016 07 14; 128(2):249-52. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27207793) Therapeutic Targeting BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. 06 23; 127(25):3225-36. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27127303) a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clin Cancer Res. 2016 Sep 01; 22(17):4350-4355. View in: targeting in multiple Cancer Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. J Bone Miner Res. 2016 06; 31(6):1225-34. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26763740) Impact of Genes Highly Myeloma on the Survival of Non-MMSET Myeloma 2016 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26847058) miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J. 2016 Jan 15; 6:e380. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26771806) Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. Cancer Res. 2016 Jan 15; 76(2):463-71. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26744527) The KDM3A-KLF2-IRF4 axis 7:10258. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26728187) Next-Generation Sequencing Oncol Educ Book. Extramedullary Correlation of FDG-PET/CT Findings With Nucl Med. 2016 Jan; View in: combinations improve patients. Leukemia. 2016 05; 30(5):1071-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26669975) Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 Mar 03; 127(9):1138-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26675349) Deep Response in Multiple Myeloma: Review. Int. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26783530) Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study. Clin Cancer Res. 2016 Mar 15; 22(6):1378-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26644410) Combination of a Selective a Signaling Pathway Inhibitor Th17 ROR?t, Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Cancer Res. 2016 Mar 01; 22(5):1222-33. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26527748) Association of Agent Orange Solitary Myeloma Presenting Small Bowel Emerg Med. 2016 Jan; 50(1):e25-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26437806) SAR650984 death via lysosomal-associated and apoptotic pathways, which is further enhanced by 2016 30(2):399-408. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26338273) Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma. Leukemia. 2016 Feb; 30(2):379-89. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26293646) Pathway Abrogates in Cancer Res. 2015 Oct 15; 75(20):4384-4397. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26249174) Placebo-Controlled Antibody) in Patients With Multicentric Castleman Disease. Cancer Res. 2015 Oct 01; 21(19):4294-304. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26124203) Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50. View in: The Cyclophilin promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26005854) A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Res. 2015 Sep 15; 21(18):4055-61. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25999435) Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18. View in: Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors. J Leuk (Los Angel). 2015 Jun; 3(2). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27668268) Pathogenesis beyond the 2015 Apr; 8(2):207-16. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25736164) Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015 Jun; 169(6):851-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25833301) Multimodality imaging and clinical features in Castleman disease: single institute experience in 30 patients. Br J Radiol. 2015 May; 88(1049):20140670. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25710283) Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015 Jun; 29(6):1441-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25634684) Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the experience. Blood. 2015 Mar 26; 125(13):2095-100. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25636340) Genetics of Mar 19; 125(12):1870-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25628468) A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol. 2015 T lymphocytes against breast cancer, colon cancer, pancreatic cancer cells. Oncoimmunology. 2014; 3(12):e970914. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25941601) Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology Am Soc 2015 Feb; 29(2):510-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25306900) Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. Elife. 2014 Oct 01; 3. View Oct; 28(5):927-43. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25212890) Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma. 2015 May; 56(5):1252-60. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25120049) Differential and limited expression of mutant alleles in multiple myeloma. Blood. 2014 Nov 13; 124(20):3110-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25237203) Pyk2 promotes tumor progression Blood. 124(17):2675-86. View BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. macroglobulinemia (WM) related disorders: View in: mediates 29(2):474-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24962017) Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24958808) CCR6, the sole cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia. 2015 Jan; 29(1):218-29. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24935722) Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma. J Clin Oncol. 2016 Jan 10; 34(2):e1-5. View in: Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24761838) Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. Leukemia. 2014 Nov; 28(11):2229-34. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24732597) Processed pseudogenes 2014 Apr in: in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24622324) miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/\u00df-catenin/BCL9 pathway. Cancer Res. 2014 Mar 15; Novel anti-B-cell maturation (GSK2857916) selectively killing of myeloma. Blood. 2014 May 15; 123(20):3128-38. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24569262) A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and 2014 06; 123(10):1461-9. View in: to IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24292625) A novel rapid-onset high-penetrance plasmacytoma model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice. Blood Cancer J. 2013 Nov 01; 3:e156. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24185503) The shaping and functional consequences of the dosage effect landscape in multiple myeloma. BMC Genomics. 2013 Oct 02; of telomeres: importance in etiology of esophageal cancer and as therapeutic target. Transl Res. 2013 Dec; 162(6):364-70. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24090770) 2013 IgG Chem Phys. 2013 Sep 28; 139(12):121904. T lymphocyte epitopes derived from HLA-DO\u00df as a novel target for multiple myeloma. Br J Haematol. 2013 Nov; 163(3):343-51. View Feb; 28(2):269-77. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23974982) Signatures of mutational processes in cancer. Nature. Aug 22; 500(7463):415-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23945592) Transcription factor-pathway between SP1 and ESR1 on dysregulating cell cycle arrest in 28(4):894-903. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23925045) Histone deacetylase 3 as a therapeutic target Leukemia. 2014 Mar; View Jul 10; 31(20):2523-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23733782) International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013 autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23685836) Challenges in May; Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor 2014 Mar 20; 33(12):1495-505. View in: impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014 Jan; 28(1):155-65. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23588715) In vitro and of novel alkylating agent, melphalan-flufenamide, against myeloma cells. Jun 01; 19(11):3019-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23584492) Proceedings of in the treatment of multiple myeloma. Clin Cancer Res. 2013 Jul 01; 19(13):3337-44. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23515406) Classify hyperdiploidy status of multiple patients using expression profiles. PLoS One. 2013; 8(3):e58809. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23554930) Targeting miR-21 inhibits vitro and in vivo multiple myeloma cell growth. Clin Cancer Res. 2013 Apr 15; 19(8):2096-106. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23418540) in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14; 121(11):2051-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23321251) humans. Blood. 2013 Apr 11; 121(15):2975-87. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23321256) Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013 Feb 01; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23293352) Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and Mar 121(11):1961-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23243282) Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis. 2012 Nov 29; 3:e436. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23190608) Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop. Br 2013 Jan; 160(2):171-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23150997) Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012 Nov 15; 18(22):6260-70. small induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11; 22(3):345-58. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22975377) Targeting NAD+ salvage pathway disruption of the BCL9/\u00df-catenin complex inhibits oncogenic Wnt signaling. Sci Transl 22; 4(148):148ra117. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22914623) Minor clone provides a [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22847421) Canonical Dec 13; 120(25):5002-13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22821765) Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res. tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012 Aug of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun 14; 119(24):5772-81. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22538852) The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur Haematol. in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth. Cancer Genomics Proteomics. 2012 Mar-Apr; 9(2):55-66. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22399496) Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012 Feb 21; 9(3):135-43. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22349016) Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8. for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22289890) Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22267603) Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented Blood. 2012 Mar 01; 119(9):2074-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22246035) Management of 2012 Apr; 26(4):595-608. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22193964) The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J 2012 88(1):1-7. View in: with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. 2011 Nov 2011 lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol. 2011 Nov; 155(3):349-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21902685) sp1 multiple Cancer Res. 17(20):6500-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21856768) Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62. View and XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia. 2011 Oct; 25(10):1610-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21660045) MGUS and Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood. 2011 Jul 21; 118(3):675-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21628407) A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21630305) Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study. J Clin Oncol. 2011 May 20; 29(15_suppl):8074. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28023488) Complete thalidomide and a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and the Aurora kinase and either alone or in combination with lenalidomide. Clin Res. 2011 May roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. Oncogene. 2011 Aug [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21423218) 17(6):1234-42. View in: dChip survival 09; Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, View Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011 May 05; 117(18):4696-700. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21292777) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 05; 117(18):4691-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21292775) Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 May 05; 117(18):4701-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21292778) Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib for in vivo expansion of human primary multiple myeloma cells. Leukemia. 2011 Apr; 25(4):707-11. View in: cyclin-dependent kinase inhibition in myeloma: biological and 2011 Feb; 152(4):420-32. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21223249) sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy. dendritic cells. Leukemia. 25(1):161-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21102427) Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Jan 13; 117(2):393-402. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21030562) MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood. 2010 Oct 20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20962322) Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28; 116(17):3227-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20651070) Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20694078) PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010 Sep 02; 116(9):1460-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20505158) The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21415962) Mechanism of action of immunomodulatory multiple Oncol. produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20395418) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 115(25):5202-13. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20382844) to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20228816) A proto-oncogene BCL6 the bone marrow microenvironment in multiple myeloma cells. Blood. 2010 May 06; 115(18):3772-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20228272) Blockade of the MEK/ERK signalling AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and J Haematol. 2010 May; 149(4):537-49. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20331454) Tailoring treatment for myeloma patients with relapsed disease. osteolysis and is promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5124-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20194748) May; 95(5):845-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20133895) Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22; 29(16):2325-36. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20101221) The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010 Apr 08; 115(14):2827-34. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19965618) Interactions of the Hdm2/p53 may enhance the antitumor activity of 2009 Dec high-affinity fully for the treatment of multiple myeloma. Res. 2009 Dec 01; 15(23):7144-52. View in: interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 06; 16(4):309-23. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19800576) Novel therapies in relapsed and 2009 Dec; 147(5):672-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19751238) The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009 Dec; 23(12):2222-32. View in: in the management Sep 08; 1:107-17. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21188129) High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15; 15(18):5829-39. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19737962) 2009 27(27):4585-90. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19687334) Identification novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood. 2009 Oct 08; 114(15):3276-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19587378) Antimyeloma activity rapamycin Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19561323) International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor 23(10):1904-12. bortezomib previously untreated myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. cytotoxicity myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15; 15(12):4028-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19509164) Use of alternate splicing to identify subgroups in uniformly treated newly-diagnosed myeloma. J Clin Oncol. 2009 May 20; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27962617) Clinical and biological significance of microRNA profiling in patients with myeloma. J nuclear View Blood. 2009 Jul 09; 114(2):371-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19417213) Emerging May 21; 113(21):5228-36. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19270264) Sinus tracts--an early tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009 Apr 30; 113(18):4341-51. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19139079) cyclin-dependent kinase inhibitor in the [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19118065) Dysfunctional homologous recombination mediates genomic and progression myeloma. Blood. 2009 Mar 05; 113(10):2290-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19050310) Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood. 2009 Feb 12; 113(7):1513-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19018094) Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res. In vivo anti-myeloma activity and modulation of gene profile induced by valproic acid, a histone deacetylase research author reply 423-4. effect of telomerase Lenalidomide inhibits osteoclastogenesis, survival Leukemia. Oct; 22(10):1925-32. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18596740) Bortezomib organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008 Jul 01; 68(13):5216-25. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18593922) Lenalidomide plus dexamethasone is efficacious multiple SNP-array analysis to identify novel chromosomal abnormalities that predict survival in multiple myeloma. J Clin Oncol. 2008 May 20; 26(15_suppl):8522. of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM). J vivo. Leukemia. 2008 Jul; 22(7):1410-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18449204) Case records of the Massachusetts General Hospital. Case 13-2008. A 46-year-old man with rheumatoid arthritis and lymphadenopathy. N characterization multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer J Haematol. 2008 May; 141(5):598-606. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18397345) Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. 2008 Feb 01; 14(3):865-74. interactions [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18216294) MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 105(4):1285-90. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18202175) Plasma cell disorders: Educ Program. 2008; 297. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19074099) Investigative Hematol Educ 2007 Dec; 82(12):1457-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18053450) role the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. Feb 01; 111(3):1654-64. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18006697) A practical guide to achieving and maintaining the best response to lenalidomide in multiple in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17854307) B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008 Aug 15; 112(4):1329-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17906076) Biological pathways 21(12):2519-26. View of of survivin and cytotoxicity in human multiple myeloma J Haematol. 2007 Sep; 138(6):783-91. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17760810) Integration myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007 Jul 01; 101(4):950-68. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17546631) Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol. 2007 Jun in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17602058) Does maintenance Sep 01; 110(5):1656-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17510321) The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17418411) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007 Feb; 13(2):183-96. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17241924) The treatment of Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007 Mar 15; 109(6):2604-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17138816) Can thalidomide improve in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and 01; 109(5):2001-7. View in: mitochondrial factor Smac/DIABLO as for multiple (MM). Blood. 2007 Feb 01; 109(3):1220-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17032924) Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor Blood. Bcl-2/Bcl-X(L)/Bcl-w inhibitor inhibitor, blocks myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 01; 12(19):5887-94. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17020997) Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J and DNA repair in multiple myeloma cells. Br J Haematol. 2006 Oct; 135(1):52-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16925573) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15; 108(10):3458-64. View R-etodolac dexamethasone in multiple in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16803565) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006 Jul 01; 66(13):6675-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16818641) Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006 Jul; 134(2):145-56. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16846475) Specific killing of myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood. 2006 Oct 15; 108(8):2804-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16809610) Novel model to evaluate changes in gene expression profile of myeloma cells in vivo following interaction with human BM previously myeloma (MM): of a phase II multicenter study. human Clinical Oncol. 2006 Jun Waldenstrom's 2006 Aug; 17(8):1275-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16788002) The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16728695) FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol. 2006 Mar; an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2005 Dec 15; 65(24):11712-20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16357183) Antimyeloma activity Feb 01; 107(3):1092-100. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16234364) Dysfunctional T regulatory cells in myeloma. Blood. 2006 Jan 01; 107(1):301-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16150935) Emerging trends in the antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant. 2005 Aug; 4:24. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16022731) Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005 Jul 01; 65(13):5898-906. View in: 2005 Jul; of a humanized anti-CD40 monoclonal antibody (SGN-40) in the inhibitor, overcomes drug resistance via down-regulation of telomerase resulting in telomere multiple and induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer 2005 01; 11(11):4251-8. View SCID-hu in 2005 characterization of PS-341 for overcoming resistance using lysophosphatidic acid 2005 Aug 01; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15827128) A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood. R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood. multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005 Jun 01; 105(11):4470-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15705788) Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15; 105(10):3945-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15692072) Proteasomal against 23(54):8766-76. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15480425) Focus on Nov; 6(5):439-44. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15542427) A global expression-based analysis consequences of the t(4;14) translocation in myeloma. Clin Cancer Res. 2004 CC-5013 activity Dec 01; 104(12):3688-96. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15292058) bone CD154 (CD40 ligand) in Waldenstrom's macroglobulinemia and may tumor cell growth through CD154/CD40 pathway. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6555. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28016960) the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple 01; 64(13):4629-36. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15231675) Multicentric plasma cell bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. Oct 15; 104(8):2458-66. View in: Growth arrest, apoptosis, which SGN-40, antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15087402) Recent advances in 65(2):634-41. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14717935) Telomerase inhibition and after telomestatin treatment in multiple myeloma. Clin Cancer Res. 2004 and clinical implications. Proc Natl Acad Sci U S A. 15; 103(8):3158-66. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15070698) Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003 myeloma. Oncogene. 2003 Nov 22(52):8386-93. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14627979) Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004 Jan 15; 103(2):656-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14563636) Fluorescence imaging of multiple a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. telomerase RNA in human multiple Res. 2003 Oct 01; 63(19):6187-94. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14559802) Immunomodulatory drug costimulates T 103(5):1787-90. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/13679868) Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res. 2003 Sep 15; 63(18):5850-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14522909) Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004 Mar 01; 103(5):1799-806. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12969976) Telomerase inhibition and transformation of MGUS to myeloma using microarray expression 2003 Dec 15; 102(13):4504-11. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12947006) DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Jul of Smac in multiple myeloma cells and confers dexamethasone Blood. 2003 Nov 01; 102(9):3379-86. View is a potent deacetylase inhibitor with significant activity against multiple myeloma. 102(7):2615-22. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12816865) CD8+ 2003 Jun; 121(6):842-8. for in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop apoptosis in multiple myeloma (MM) cells. 16; 278(20):17593-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12665525) Infection--an underappreciated cause of J Haematol. 2003 Mar; 120(6):1047-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12648075) Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003 May 15; 101(10):3849-56. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12531801) Molecular sequelae of histone deacetylase human cells. 101(10):4055-62. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12531799) translocation of reverse transcriptase protein. insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. Biol Chem. 2003 Feb 21; 278(8):5794-801. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12482878) Identification of genes regulated (2ME2) in multiple myeloma cells using in: human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. cells to chemotherapeutic agents: therapeutic applications. Blood. 2003 Molecular cells. Proc Acad S A. 2-Methoxyestradiol overcomes drug resistance in cells. Blood. 2002 Sep 15; 100(6):2187-94. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12200384) Clinical activity of arsenic trioxide the treatment vivo and prolongs survival in a murine model. Cancer Res. Sep 01; 62(17):4996-5000. View PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26. View in: inhibitors intracellular anti-apoptotic via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Aug 22; 21(37):5673-83. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12173037) Arsenic trioxide inhibits growth of multiple myeloma cells in the bone marrow microenvironment. Mol Aug; 1(10):851-60. 76 Suppl 1:340-1. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12430878) beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp activity in a human multiple myeloma cell line. Cancer Res. 2002 Jul 01; 62(13):3876-82. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12097303) Apoptotic in myeloma cells: Biologic sequelae of nuclear factor-kappaB multiple Blood. 2002 Jun 01; 99(11):4079-86. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12010810) Adeno-associated virus protects the retinoblastoma family of proteins from adenoviral-induced functional inactivation. Cancer Res. 2002 May 15; 62(10):2982-5. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12019182) in: as a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10; 277(19):16639-47. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11872748) Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene. 2002 Feb 21; 21(9):1346-58. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11857078) ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion. 2002 Feb; 42(2):205-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11896336) Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol. 2002 116(1):211-7. Rep78 with SV40 T antigen: implications in Rep protein expression leading to the inhibition of SV40-mediated cell proliferation. Intervirology. interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 Dec 06; 345(23):1655-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11759643) Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol. 2001 Dec; 28(6):565-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11740810) Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001 Sep; 114(4):822-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11564069) Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001 Sep; 114(3):600-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11552985) Coordination of 2001 Aug 10; 293(5532):1133-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11498590) in advanced multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001 Jul 15; 98(2):492-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11435324) Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. Cancer Res. 2001 Jun 01; 61(11):4583-90. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11389094) High response rate in poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor infusions. Blood. 2001 May 97(9):2574-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11294829) CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities. AJNR Am J Neuroradiol. 2001 Apr; 22(4):781-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11290500) Expression of a free gamma heavy chain in serum following autologous stem cell transplantation for IgG kappa multiple myeloma. Bone Marrow Transplant. 2001 Mar; 27(6):663-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11319600) Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein. Exp Hematol. 2001 Jan; 29(1):85-92. View in: Rep proteins in SV40-transformed and untransformed cells: reciprocal interaction with View in: 2:17-21. View load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11167811) Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol. 2001 Jan; 112(1):167-74. View myeloma idiotype-induced cells. Blood. 20(20):7572-82. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11003653) The architectural transcription factor high mobility group I(Y) participates in photoreceptor-specific gene expression. J Neurosci. 2000 Oct 01; 20(19):7317-24. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11007889) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000 Jun 15; 95(12):4008-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10845942) Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant. 2000 Mar; 25(5):483-7. View c-Src vascular endothelial growth factor stimulation in Kaposi's 2000 Feb 01; 164(3):1169-74. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10640727) A phase II trial of high dose epirubicin in patients with advanced breast carcinoma. Cancer. 2000 Jan 15; 88(2):375-80. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10640971) kinase and focal tyrosine kinase/proline-rich marrow stromal cells as a vehicle for gene transfer. Gene Ther. 1999 09; 6(9):1611-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10490771) Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy. Bone Marrow Transplant. 1999 Sep; 24(5):505-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10482934) Interaction of adeno-associated virus Rep78 with p53: implications in growth inhibition. Cancer Res. 1999 Aug 01; 59(15):3592-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10446967) Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-alpha therapy. Bone Marrow Transplant. 1999 Jul; 24(1):13-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10435728) Recent advances in Hematol. of HMG I(Y) the assembly and function of the IFN-beta syndrome complicating J Haematol. 1999 Jun; 105(4):993-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10554812) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999 Jan 01; 93(1):55-65. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9864146) Age is not a prognostic variable with autotransplants for multiple myeloma. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9864145) Lymphomatoid granulomatosis following Jan; 23(1):79-81. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10037054) The IFN-beta enhancer: a paradigm for understanding activation and repression of inducible gene expression. Cold Spring Harb Symp Quant Biol. 1999; small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology clinical Chemother by enhanceosome. Cell. 1998 2(4):457-67. receptor, kinases, and components of to or relapsing after a first-line 1998 May; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9613780) Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood. May colony-stimulating or in Oncol. 1998 Apr; 16(4):1547-53. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9552064) In vitro packaging of an infectious recombinant adeno-associated virus 2. Gene Ther. 1997 Nov; 4(11):1167-72. View in: 1997 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9298757) Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and transplantation for multiple myeloma relapsing after a previous transplant. Bone Marrow Transplant. 1997 Jul; 20(2):113-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9244413) Single weekly cytosine arabinoside and 6-thioguanine in patients with myelodysplastic syndrome and acute myeloid can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood. 1997 Feb 15; 89(4):1334-40. Feb; and therapy expression in cells from the p6 promoter of human parvovirus B19 following plasmid transfection adeno-associated infection: human megakaryocytic leukaemia cells are non-permissive for AAV infection. J Gen Pt 6):1111-22. View in: View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8562947) Adeno-associated virus 2-mediated gene transfer expression human granulocyte-macrophage factor. Exp Hematol. 1995 Nov; 23(12):1261-7. View in: Effect of tumor irradiation on the uptake of lymphokine-activated killer cells in a murine tumor model. Cancer Res. 1994 Apr 01; 54(7):1657-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8137277) Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer. Invest New Drugs. 1993 May-Aug; 11(2-3):203-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8262732) Phase II study of 186641). A novel antineoplastic agent in advanced non-small cell lung cancer. Invest New Drugs. 1993 Feb; 11(1):87-90. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8394298) Successful replication of parvovirus B19 the human leukemia cell 1993 uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors. Invest New Drugs. 1992 Aug; 10(3):159-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1428725) Growth factor-dependent initiation of DNA replication in nuclei isolated from an interleukin 3-dependent murine myeloid cell line. "}